Mubadala, Hedge Fund Tycoons Finance Longevity Biotech Rejuveron - Bloomberg
Swiss biotech firm Rejuveron Life Sciences AG has attracted backing from sovereign fund Mubadala Investment Co. to help bankroll its development of drugs targeting the effects of aging, people familiar with the matter said.
Rejuveron has raised about $75 million from a series B funding round and convertible loan deal, the people said. Investors in the fundraising include Catalio Capital Management, the life sciences-focused firm backed by hedge fund billionaires Stan Druckenmiller and Alan Howard, the people said.
German entrepreneur Christian Angermayer, a founding investor in Rejuveron, is also providing more funds alongside Mubadala’s asset management arm Mubadala Capital and various family offices, the people said. The fundraising values Rejuveron at nearly $400 million, the people said.
Rejuveron is developing therapies to prevent or reverse diseases of aging and extend people’s lifespans. It’s running clinical trials for treatments targeting retinitis pigmentosa, a group of rare eye diseases that cause progressive vision loss, as well as sarcopenia, a condition that causes muscle loss as a person gets older.
No comments:
Post a Comment